Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2008 1
2009 5
2010 4
2011 1
2012 2
2014 3
2015 7
2016 7
2017 2
2018 5
2019 5
2020 2
2021 2
Text availability
Article attribute
Article type
Publication date

Search Results

38 results
Results by year
Filters applied: . Clear all
Page 1
Anticytokine Immune Therapy and Atherothrombotic Cardiovascular Risk.
Ait-Oufella H, Libby P, Tedgui A. Ait-Oufella H, et al. Arterioscler Thromb Vasc Biol. 2019 Aug;39(8):1510-1519. doi: 10.1161/ATVBAHA.119.311998. Epub 2019 Jul 11. Arterioscler Thromb Vasc Biol. 2019. PMID: 31294625 Free PMC article. Review.
Other clinical studies support the protective effects of treatment with anti-TNF-alpha and anti-IL-6 receptor monoclonal antibodies on cardiovascular risk. Blockade of the IL-23/IL-17 axis, however, warrants caution as a cardiovascular in …
Other clinical studies support the protective effects of treatment with anti-TNF-alpha and anti-IL-6 receptor monoclona …
Psoriasis, Cardiovascular Events, and Biologics: Lights and Shadows.
Caiazzo G, Fabbrocini G, Di Caprio R, Raimondo A, Scala E, Balato N, Balato A. Caiazzo G, et al. Front Immunol. 2018 Aug 13;9:1668. doi: 10.3389/fimmu.2018.01668. eCollection 2018. Front Immunol. 2018. PMID: 30150978 Free PMC article. Review.
In particular, anti-TNF-alpha agents seem to reduce these events in psoriasis patients whereas anti-IL-12/23 agents related CV events reduction still remain to clarify. It has to be taken into account that IL-12/23 inhibitors have a shorter post-market …
In particular, anti-TNF-alpha agents seem to reduce these events in psoriasis patients whereas anti-IL-12/23 age …
Psoriasis and Inflammatory Bowel Disease.
Cottone M, Sapienza C, Macaluso FS, Cannizzaro M. Cottone M, et al. Dig Dis. 2019;37(6):451-457. doi: 10.1159/000500116. Epub 2019 May 10. Dig Dis. 2019. PMID: 31079092 Free article. Review.
IBD and PS have in common some comorbidities like cardiovascular disease, similar risk of cancer and psychiatric problems. Many biological therapies such as anti-tumour necrosis factor (TNF) and anti-interleukin 23 are effective in …
IBD and PS have in common some comorbidities like cardiovascular disease, similar risk of cancer and psychiatric proble …
Pharmacological treatment of psoriatic arthritis: a systematic literature research for the 2019 update of the EULAR recommendations for the management of psoriatic arthritis.
Kerschbaumer A, Smolen JS, Dougados M, de Wit M, Primdahl J, McInnes I, van der Heijde D, Baraliakos X, Falzon L, Gossec L. Kerschbaumer A, et al. Ann Rheum Dis. 2020 Jun;79(6):778-786. doi: 10.1136/annrheumdis-2020-217163. Epub 2020 May 7. Ann Rheum Dis. 2020. PMID: 32381564
RESULTS: 56 publications (efficacy: n=33; safety n=23) were analysed. The articles were on tumour necrosis factor (TNF) inhibitors (n=6; golimumab, etanercept and biosimilars), interleukin (IL)-17A inhibitors (n=10; ixekizumab, secukinumab), IL-23-p19 inhibitors (n=2; guse …
RESULTS: 56 publications (efficacy: n=33; safety n=23) were analysed. The articles were on tumour necrosis factor (TNF) inhibitors (n …
Effects of anti-TNF-alpha agents on circulating endothelial-derived and platelet-derived microparticles in psoriasis.
Pelletier F, Garnache-Ottou F, Biichlé S, Vivot A, Humbert P, Saas P, Seillès E, Aubin F. Pelletier F, et al. Exp Dermatol. 2014 Dec;23(12):924-5. doi: 10.1111/exd.12551. Exp Dermatol. 2014. PMID: 25255926
We investigated the effect of TNF blockers on microparticles levels before and after treatment in patients (twenty treated by anti-TNF-alpha agents and 6 by methotrexate) with severe psoriasis. ...Then, TNF blockade may be effective to reduce …
We investigated the effect of TNF blockers on microparticles levels before and after treatment in patients (twenty treated by anti
Anti-TNF-alpha therapy improves insulin sensitivity in non-diabetic patients with psoriasis: a 6-month prospective study.
Pina T, Armesto S, Lopez-Mejias R, Genre F, Ubilla B, Gonzalez-Lopez MA, Gonzalez-Vela MC, Corrales A, Blanco R, Garcia-Unzueta MT, Hernandez JL, Llorca J, Gonzalez-Gay MA. Pina T, et al. J Eur Acad Dermatol Venereol. 2015 Jul;29(7):1325-30. doi: 10.1111/jdv.12814. Epub 2014 Oct 29. J Eur Acad Dermatol Venereol. 2015. PMID: 25353352
OBJECTIVE: Psoriasis is a chronic inflammatory disease associated with increased risk of cardiovascular death. ...CONCLUSION: Our results support a beneficial effect of the anti-TNF-alpha blockade on the mechanisms associated with acceler …
OBJECTIVE: Psoriasis is a chronic inflammatory disease associated with increased risk of cardiovascular death. . …
Short-term risk of major adverse cardiovascular events or congestive heart failure in patients with psoriatic arthritis or psoriasis initiating a biological therapy: a meta-analysis of randomised controlled trials.
Champs B, Degboé Y, Barnetche T, Cantagrel A, Ruyssen-Witrand A, Constantin A. Champs B, et al. RMD Open. 2019 Jan 24;5(1):e000763. doi: 10.1136/rmdopen-2018-000763. eCollection 2019. RMD Open. 2019. PMID: 30792887 Free PMC article.
OBJECTIVE: The objective was to investigate the short-term risk of major adverse cardiovascular events (MACEs) or congestive heart failure (CHF) in patients with psoriatic arthritis (PsA) or psoriasis initiating a biological therapy. ...No signi …
OBJECTIVE: The objective was to investigate the short-term risk of major adverse cardiovascular events (MACEs) or congestive …
Psoriasis and cardiovascular disorders.
Ryan C, Menter A. Ryan C, et al. G Ital Dermatol Venereol. 2012 Apr;147(2):179-87. G Ital Dermatol Venereol. 2012. PMID: 22481581 Review.
There is considerable evidence to show that patients with moderate-to-severe psoriasis have a significantly increased risk of cardiovascular disease and cardiovascular risk factors such as obesity, diabetes mellitus, the metabolic …
There is considerable evidence to show that patients with moderate-to-severe psoriasis have a significantly increased risk of …
Anti-TNF-alpha therapy reduces retinol-binding protein 4 serum levels in non-diabetic patients with psoriasis: a 6-month prospective study.
Pina T, Genre F, Lopez-Mejias R, Armesto S, Ubilla B, Mijares V, Dierssen-Sotos T, Corrales A, Gonzalez-Lopez MA, Gonzalez-Vela MC, Blanco R, Llorca J, Gonzalez-Gay MA. Pina T, et al. J Eur Acad Dermatol Venereol. 2016 Jan;30(1):92-5. doi: 10.1111/jdv.13005. Epub 2015 Feb 4. J Eur Acad Dermatol Venereol. 2016. PMID: 25650695
OBJECTIVE: In this study, we aimed to establish the effect of anti-TNF-alpha therapy on RBP4 levels in patients with moderate-to-severe psoriasis. ...CONCLUSION: Our results support an influence of the anti-TNF-alpha blockade on RBP4 seru …
OBJECTIVE: In this study, we aimed to establish the effect of anti-TNF-alpha therapy on RBP4 levels in patients with mo …
Relationship of leptin with adiposity and inflammation and resistin with disease severity in psoriatic patients undergoing anti-TNF-alpha therapy.
Pina T, Genre F, Lopez-Mejias R, Armesto S, Ubilla B, Mijares V, Dierssen-Sotos T, Gonzalez-Lopez MA, Gonzalez-Vela MC, Blanco R, Hernández JL, Llorca J, Gonzalez-Gay MA. Pina T, et al. J Eur Acad Dermatol Venereol. 2015 Oct;29(10):1995-2001. doi: 10.1111/jdv.13131. Epub 2015 Mar 30. J Eur Acad Dermatol Venereol. 2015. PMID: 25823684
OBJECTIVE: To determine whether two adipokines, leptin and resistin, correlate with metabolic syndrome features and disease severity in psoriatic patients who underwent anti-TNF-alpha therapy. METHODS: Prospective study of consecutive non-diabetic pati …
OBJECTIVE: To determine whether two adipokines, leptin and resistin, correlate with metabolic syndrome features and disease severity …
38 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page